Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807246668> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2807246668 abstract "Introduction: Strong evidence exists linking LDL-C as a causal factor of atherosclerotic CVD. Statins are the cornerstone for lipid lowering therapy (LLT) so it is important to understand treatment trends in light of current guidelines. Objective: To evaluate LLT trends in a US real-world setting. Methods: Patients (aged ≥18y) who initiated LLT (statins and/or ezetimibe) from 01/01/2007-06/30/2011 were retrospectively identified from IMS commercial claims. Patients were classified into two cohorts: 1) Prior CVD and 2) Prior CHD RE conditions [Definitions in Figure 1] and stratified by age group (<65 and ≥65y). Eligible patients had continuous health plan enrollment for ≥1 year pre- and post-index date (LLT initiation date). The following were assessed: index statin intensity (defined by ACC/AHA 2013 guidelines), first treatment modification (e.g., switch, re-initiation after temporary discontinuation of >60 days, permanent discontinuation of all LLT) and time-to-first treatment modification. Results: A total of 41,934 patients with prior CVD (mean age: 58y) and 170,344 patients with CHD RE (mean age: 57y) were analyzed. From 2007-2011, 66.6-77.8% and 8.8-25.1% of the cohorts were prescribed moderate-intensity and high-intensity statins, respectively, on the index date. Among the CVD and CHD RE cohorts, 18.8% and 26.2% reinitiated index LLT, 11.6% and 13.2% permanently discontinued all LLT and 19.5% and 13.6% switched to a different statin, respectively, as the first treatment modification (Figure 1). A similar trend was observed among patients aged ≥65y. Average number of days to first treatment modification was 130-399 days. Conclusion: With 79% of patients modifying their index LLT, of which 12-13% permanently discontinuing all LLT, such treatment modifications may potentially be indicative of index statin intolerability and/or ineffectiveness. High-intensity statin therapy initiation is low, potentially resulting in residual risk of CVD." @default.
- W2807246668 created "2018-06-13" @default.
- W2807246668 creator A5010643980 @default.
- W2807246668 creator A5012278873 @default.
- W2807246668 creator A5043019475 @default.
- W2807246668 creator A5045372603 @default.
- W2807246668 creator A5085689787 @default.
- W2807246668 creator A5086073841 @default.
- W2807246668 date "2015-11-10" @default.
- W2807246668 modified "2023-09-22" @default.
- W2807246668 title "Abstract 14373: Treatment Trends Among High Cardiovascular Disease Risk Patients Treated With Lipid-lowering Therapies: A United States Real-world Study" @default.
- W2807246668 doi "https://doi.org/10.1161/circ.132.suppl_3.14373" @default.
- W2807246668 hasPublicationYear "2015" @default.
- W2807246668 type Work @default.
- W2807246668 sameAs 2807246668 @default.
- W2807246668 citedByCount "0" @default.
- W2807246668 crossrefType "journal-article" @default.
- W2807246668 hasAuthorship W2807246668A5010643980 @default.
- W2807246668 hasAuthorship W2807246668A5012278873 @default.
- W2807246668 hasAuthorship W2807246668A5043019475 @default.
- W2807246668 hasAuthorship W2807246668A5045372603 @default.
- W2807246668 hasAuthorship W2807246668A5085689787 @default.
- W2807246668 hasAuthorship W2807246668A5086073841 @default.
- W2807246668 hasConcept C126322002 @default.
- W2807246668 hasConcept C2776839432 @default.
- W2807246668 hasConcept C2778657065 @default.
- W2807246668 hasConcept C2778715236 @default.
- W2807246668 hasConcept C71924100 @default.
- W2807246668 hasConceptScore W2807246668C126322002 @default.
- W2807246668 hasConceptScore W2807246668C2776839432 @default.
- W2807246668 hasConceptScore W2807246668C2778657065 @default.
- W2807246668 hasConceptScore W2807246668C2778715236 @default.
- W2807246668 hasConceptScore W2807246668C71924100 @default.
- W2807246668 hasIssue "suppl_3" @default.
- W2807246668 hasLocation W28072466681 @default.
- W2807246668 hasOpenAccess W2807246668 @default.
- W2807246668 hasPrimaryLocation W28072466681 @default.
- W2807246668 hasRelatedWork W2044413524 @default.
- W2807246668 hasRelatedWork W2082804793 @default.
- W2807246668 hasRelatedWork W2266022364 @default.
- W2807246668 hasRelatedWork W2337038799 @default.
- W2807246668 hasRelatedWork W2522545396 @default.
- W2807246668 hasRelatedWork W2551697949 @default.
- W2807246668 hasRelatedWork W2781081058 @default.
- W2807246668 hasRelatedWork W2792808126 @default.
- W2807246668 hasRelatedWork W2890853826 @default.
- W2807246668 hasRelatedWork W2951530638 @default.
- W2807246668 hasRelatedWork W2981793638 @default.
- W2807246668 hasRelatedWork W2991090955 @default.
- W2807246668 hasRelatedWork W3015168671 @default.
- W2807246668 hasRelatedWork W3036177780 @default.
- W2807246668 hasRelatedWork W3092360790 @default.
- W2807246668 hasRelatedWork W3101032765 @default.
- W2807246668 hasRelatedWork W3119451454 @default.
- W2807246668 hasRelatedWork W3162158865 @default.
- W2807246668 hasRelatedWork W3208235556 @default.
- W2807246668 hasRelatedWork W2525524734 @default.
- W2807246668 hasVolume "132" @default.
- W2807246668 isParatext "false" @default.
- W2807246668 isRetracted "false" @default.
- W2807246668 magId "2807246668" @default.
- W2807246668 workType "article" @default.